BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24984238)

  • 1. Evaluation of interactions between urokinase plasminogen and inhibitors using molecular dynamic simulation and free-energy calculation.
    Sa R; Fang L; Huang M; Li Q; Wei Y; Wu K
    J Phys Chem A; 2014 Oct; 118(39):9113-9. PubMed ID: 24984238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).
    Katz BA; Luong C; Ho JD; Somoza JR; Gjerstad E; Tang J; Williams SR; Verner E; Mackman RL; Young WB; Sprengeler PA; Chan H; Mortara K; Janc JW; McGrath ME
    J Mol Biol; 2004 Nov; 344(2):527-47. PubMed ID: 15522303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
    Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
    J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of amino-acid mutations on specific interactions between urokinase-type plasminogen activator and its receptor: Ab initio molecular orbital calculations.
    Tsuji S; Kasumi T; Nagase K; Yoshikawa E; Kobayashi H; Kurita N
    J Mol Graph Model; 2011 Aug; 29(8):975-84. PubMed ID: 21605990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.
    Sperl S; Jacob U; Arroyo de Prada N; Stürzebecher J; Wilhelm OG; Bode W; Magdolen V; Huber R; Moroder L
    Proc Natl Acad Sci U S A; 2000 May; 97(10):5113-8. PubMed ID: 10805774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is inhibition process better described with MD(QM/MM) simulations? The case of urokinase type plasminogen activator inhibitors.
    Barbault F; Maurel F
    J Comput Chem; 2012 Mar; 33(6):607-16. PubMed ID: 22241532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines.
    Fish PV; Barber CG; Brown DG; Butt R; Collis MG; Dickinson RP; Henry BT; Horne VA; Huggins JP; King E; O'Gara M; McCleverty D; McIntosh F; Phillips C; Webster R
    J Med Chem; 2007 May; 50(10):2341-51. PubMed ID: 17447747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geometry of GPPE binding to picrate and to the urokinase type plasminogen activator.
    Zesławska E; Stürzebecher J; Oleksyn BJ
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6212-5. PubMed ID: 17905583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator.
    Mackman RL; Katz BA; Breitenbucher JG; Hui HC; Verner E; Luong C; Liu L; Sprengeler PA
    J Med Chem; 2001 Nov; 44(23):3856-71. PubMed ID: 11689072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
    Katz BA; Mackman R; Luong C; Radika K; Martelli A; Sprengeler PA; Wang J; Chan H; Wong L
    Chem Biol; 2000 Apr; 7(4):299-312. PubMed ID: 10779411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors.
    Katz BA; Elrod K; Verner E; Mackman RL; Luong C; Shrader WD; Sendzik M; Spencer JR; Sprengeler PA; Kolesnikov A; Tai VW; Hui HC; Breitenbucher JG; Allen D; Janc JW
    J Mol Biol; 2003 May; 329(1):93-120. PubMed ID: 12742021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
    Jankun J; Skrzypczak-Jankun E
    Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
    Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
    Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues.
    Jiang L; Zhao B; Xu P; Sørensen HP; Jensen JK; Christensen A; Hosseini M; Nielsen NC; Jensen KJ; Andreasen PA; Huang M
    Int J Biochem Cell Biol; 2015 May; 62():88-92. PubMed ID: 25744057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.
    Nagase K; Kobayashi H; Yoshikawa E; Kurita N
    J Mol Graph Model; 2009 Aug; 28(1):46-53. PubMed ID: 19403319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines.
    Barber CG; Dickinson RP; Fish PV
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3227-30. PubMed ID: 15149680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insight into the binding modes and inhibition mechanisms of adamantyl-based 1,3-disubstituted urea inhibitors in the active site of the human soluble epoxide hydrolase.
    Chen H; Zhang Y; Ye C; Feng TT; Han JG
    J Biomol Struct Dyn; 2014; 32(8):1231-47. PubMed ID: 23815795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1.
    Zhao G; Yuan C; Wind T; Huang Z; Andreasen PA; Huang M
    J Struct Biol; 2007 Oct; 160(1):1-10. PubMed ID: 17692534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA).
    Venkatraj M; Messagie J; Joossens J; Lambeir AM; Haemers A; Van der Veken P; Augustyns K
    Bioorg Med Chem; 2012 Feb; 20(4):1557-68. PubMed ID: 22285569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.